It has a unique organizational model, internally controlling all the processes of the value chain and is a benchmark in research, production and marketing of vaccines.
The Hipra project has the support of the Spanish Agency for Medicines and Health Products (Aemps), as well as the Ministries of Health, Industry and Science and Innovation.
At the moment, Hipra is also carrying out a line of research in collaboration with the Hospital Clínic de Barcelona for the development of a vaccine against covid-19 based on the mRNA of the virus.
Hipra is the laboratory that has launched the most innovative and technological vaccines in the last 10 years, with a total of 22 vaccines.
The company closed the financial year 2020 with a turnover of 319 million euros and for this 2021 it expects a growth of 13.5% compared to the previous year. Currently, Hipra’s workforce is made up of more than 2,000 people.
The company dedicates 10% of its annual turnover to research and development of new vaccines. It currently has 39 subsidiaries and 11 diagnostic centers around the world and markets its products in more than 100 countries.
Since 2019, the company has been promoting the Campus HIPRA project in Aiguaviva, which includes the expansion of its current facilities into a new complex that will house different production and research units.
As well as new business areas of the company in an area of 114,000 square meters The project foresees an investment plan of 472 million euros until 2026 and the direct creation of 580 highly qualified jobs.